richa sharma 's Entries

3 blogs
  • 10 Oct 2018
    Reflux esophagitis is an esophageal mucosal injury that occurs secondary to retrograde flux of gastric contents into the esophagus, also called gastroesophageal reflux disease (GERD). It is a condition in which the stomach contents (food or liquid) leak backwards from the stomach into the esophagus (the tube from the mouth to the stomach). This causes chronic inflammation and irritation of the esophagus. It also affects the gastroesophageal junctional mucosa. GERD is classified into two groups on the basis of mucosal changes on endoscopy, which are non-erosive reflux disease (NERD) and erosive esophagitis. NERD is defined as the presence of typical symptoms of GERD in the absence of esophageal mucosal injury on conventional upper gastrointestinal endoscopy. Erosive esophagitis is characterized by mucosal breaks such as erosions or ulcerations on endoscopy. According to study, “Reflux Esophagitis (Gastroesophageal Reflux Disease) Global Clinical Trials Review, H1, 2018” some of the major companies that are currently working in the reflux esophagitis are Chong kun dang pharmaceutical Corp, Ironwood pharmaceuticals Inc, Takeda pharmaceutical Co Ltd, YuyupharmaInc, Ahn-Gook pharmaceutical Co Ltd,CJ healthcare Corp, Eisai Co Ltd, Wockhardt Ltd, Melinta therapeutics Inc, Sun pharma advanced research company Ltd, Daewoong pharmaceutical Co Ltd, RaQualiapharma Inc. There are some pathogenesis of GERD such as gastric factors, antireflux mechanisms and esophageal clearance mechanisms. Gastric factors are defined by two terms; irritant potency of the refluxed material and delayed gastric emptying. Irritant potency of the refluxed material is depending on caustic agents such as acid, pepsin, bile & pancreatic enzymes. Delayed gastric, causes gastric distention that can stimulate gastric acid secretion & trigger TLSER (transient lower esophageal sphincter relaxation). Antireflux is a positive pressure gradient between the abdomen and the thorax that tends to promote the reflux of material from the stomach into the esophagus. Diagnosis of GERD includes two methods such as clinical representation and diagnostic tests. In clinical presentation pyrosis, dysphagia, regurgitation, water brash, odynophagia, chest pain, pulmonary symptoms and night-time GER. There are many methods for treatment of GERD such as medical treatment, antireflux surgery and endoscopic antireflux procedures. Medical treatment involves lifestyle modifications and pharmacologic therapy. In lifestyle modification smoking, alcohol, fatty meal, tea, spicy food and drugs are involves whereas in pharmacologic therapy, H2 blockers, proton pump inhibitors, antacids, prokinetic drugs and sucralfate are involves. There are a number of different antireflux operations such as nissen, toupet, belesy and fundoplication. Endoscopic antireflux procedures is defined by three system; stretta system, bard endoscopic suturing system and injection of collagen circumferentially at the LES. There are also some risk factors of GERD; which are scleroderma, alcohol, pregnancy, hiatal hernia, cigarettes and obesity etc. there are also two complications of GERD; peptic stricture formation and barrett’s esophagus. Peptic stricture is a lumen-narrowing lesion that occurs in erosive esophagitis secondary to edema, inflammation or fibrosis of the distal end of esophagi. Barrett’s esophagua is replacement of reflux-damaged squamous epithelium in the distal part of esophagus by metaplastic. Globally, gastroesophageal reflux disease has been increasing in east due to the socioeconomic development. The prevalence of both GERD and functional gastrointestinal disorders (FGIDs) ranges between 10% and 25% worldwide. Improved medical therapy for GERD might depend on future agents with different therapeutic targets, including GABA inhibitors and nitric oxide modulating drugs in the control of the lower sphincter esophagus and in motility disorders, free radical scavengers in the prevention of mucosal damage and COX-2 specific inhibitors in the prevention of the progression of Barret's esophagus to adenocarcinoma. To know more, click on the link below:- https://www.kenresearch.com/healthcare/pharmaceuticals/reflux-esophagitis-global/154890-91.html Related Reports:- https://www.kenresearch.com/healthcare/pharmaceuticals/reflux-esophagitis-gastroesophageal/10424-91.html https://www.kenresearch.com/healthcare/general-healthcare/reflux-esophagitis-gastroesophageal-reflux-disease-pipeline-review/142753-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Sales@kenresearch.com +91-9015378249
    1050 Posted by richa sharma
  • Reflux esophagitis is an esophageal mucosal injury that occurs secondary to retrograde flux of gastric contents into the esophagus, also called gastroesophageal reflux disease (GERD). It is a condition in which the stomach contents (food or liquid) leak backwards from the stomach into the esophagus (the tube from the mouth to the stomach). This causes chronic inflammation and irritation of the esophagus. It also affects the gastroesophageal junctional mucosa. GERD is classified into two groups on the basis of mucosal changes on endoscopy, which are non-erosive reflux disease (NERD) and erosive esophagitis. NERD is defined as the presence of typical symptoms of GERD in the absence of esophageal mucosal injury on conventional upper gastrointestinal endoscopy. Erosive esophagitis is characterized by mucosal breaks such as erosions or ulcerations on endoscopy. According to study, “Reflux Esophagitis (Gastroesophageal Reflux Disease) Global Clinical Trials Review, H1, 2018” some of the major companies that are currently working in the reflux esophagitis are Chong kun dang pharmaceutical Corp, Ironwood pharmaceuticals Inc, Takeda pharmaceutical Co Ltd, YuyupharmaInc, Ahn-Gook pharmaceutical Co Ltd,CJ healthcare Corp, Eisai Co Ltd, Wockhardt Ltd, Melinta therapeutics Inc, Sun pharma advanced research company Ltd, Daewoong pharmaceutical Co Ltd, RaQualiapharma Inc. There are some pathogenesis of GERD such as gastric factors, antireflux mechanisms and esophageal clearance mechanisms. Gastric factors are defined by two terms; irritant potency of the refluxed material and delayed gastric emptying. Irritant potency of the refluxed material is depending on caustic agents such as acid, pepsin, bile & pancreatic enzymes. Delayed gastric, causes gastric distention that can stimulate gastric acid secretion & trigger TLSER (transient lower esophageal sphincter relaxation). Antireflux is a positive pressure gradient between the abdomen and the thorax that tends to promote the reflux of material from the stomach into the esophagus. Diagnosis of GERD includes two methods such as clinical representation and diagnostic tests. In clinical presentation pyrosis, dysphagia, regurgitation, water brash, odynophagia, chest pain, pulmonary symptoms and night-time GER. There are many methods for treatment of GERD such as medical treatment, antireflux surgery and endoscopic antireflux procedures. Medical treatment involves lifestyle modifications and pharmacologic therapy. In lifestyle modification smoking, alcohol, fatty meal, tea, spicy food and drugs are involves whereas in pharmacologic therapy, H2 blockers, proton pump inhibitors, antacids, prokinetic drugs and sucralfate are involves. There are a number of different antireflux operations such as nissen, toupet, belesy and fundoplication. Endoscopic antireflux procedures is defined by three system; stretta system, bard endoscopic suturing system and injection of collagen circumferentially at the LES. There are also some risk factors of GERD; which are scleroderma, alcohol, pregnancy, hiatal hernia, cigarettes and obesity etc. there are also two complications of GERD; peptic stricture formation and barrett’s esophagus. Peptic stricture is a lumen-narrowing lesion that occurs in erosive esophagitis secondary to edema, inflammation or fibrosis of the distal end of esophagi. Barrett’s esophagua is replacement of reflux-damaged squamous epithelium in the distal part of esophagus by metaplastic. Globally, gastroesophageal reflux disease has been increasing in east due to the socioeconomic development. The prevalence of both GERD and functional gastrointestinal disorders (FGIDs) ranges between 10% and 25% worldwide. Improved medical therapy for GERD might depend on future agents with different therapeutic targets, including GABA inhibitors and nitric oxide modulating drugs in the control of the lower sphincter esophagus and in motility disorders, free radical scavengers in the prevention of mucosal damage and COX-2 specific inhibitors in the prevention of the progression of Barret's esophagus to adenocarcinoma. To know more, click on the link below:- https://www.kenresearch.com/healthcare/pharmaceuticals/reflux-esophagitis-global/154890-91.html Related Reports:- https://www.kenresearch.com/healthcare/pharmaceuticals/reflux-esophagitis-gastroesophageal/10424-91.html https://www.kenresearch.com/healthcare/general-healthcare/reflux-esophagitis-gastroesophageal-reflux-disease-pipeline-review/142753-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Sales@kenresearch.com +91-9015378249
    Oct 10, 2018 1050
  • 09 Oct 2018
    A bone marrow transplant is a procedure that infuses healthy blood stem cells into your body to replace your damaged or diseased bone marrow. A bone marrow transplant is also called a stem cell transplant. A bone marrow transplant may be necessary if bone marrow stops working and doesn't produce enough healthy blood cells. Bone marrow transplant (BMT) rejection is a complication that can occur after a stem cell or bone marrow transplant. This is occurring when newly transplanted donor cells attack the transplant recipient's body. It also happens when the cells from donor are not accepted by patient’s body and patient’s original condition comes back, called as relapse. The chance of BMT rejection is around 30%-40%, when the donor and recipients are related and it is 60%-80% when the donor and recipient are not related. According to study, “Bone Marrow Transplant Rejection - Pipeline Review, H2 2018” some of the major players operating in BMT rejection are Bellicum Pharmaceuticals, Inc., Bio-Cancer Treatment International Limited, Actelion Ltd, BiogenInc, -Myers Squibb Company, Cantex Pharmaceuticals, Inc., Boryung Pharmaceutical Co., Ltd., Bristol Capricor Therapeutics, Inc., Dr. Falk Pharma GmbH, Cell Source Inc., Escape Therapeutics, Inc., Fate Therapeutics, Inc., Gilead Sciences, Inc.,F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Kamada Ltd., KiadisPharma N.V., Kymab Limited, Kyorin Pharmaceutical Co., Ltd., MacroGenics, Inc., Mallinckrodt Plc, Medsenic, Mesoblast Limited,  Rigel Pharmaceuticals, Inc., Seattle Genetics, Inc., Sarepta Therapeutics, Inc., Sigmoid Pharma Limited, Taiga Biotechnologies Inc., Spherium Biomed S.L. There are many symptoms of BMT rejection such as chills, chest pain, fever, and drop in blood pressure, flushing, hives, nausea, and headache, funny taste in mouth and pain & shortness of breath. The some of the problem associated with bone marrow transplant rejection include abnormal lymph tissues growth, hormone changes, cataracts, relase, secondary cancer and organ damage and others. Moreover these problems are dependent on important factors such as patient’s health, patient’s age, the length & degree of immune system suppression and chronic gast versus host disease is present or not. Primarily two approach to prevent BMT rejection at the transplant centers. The first treatment includes immunosuppressive drugs. It prevents BMT rejection by eradicating host T-cells to allow acceptance of donor cells. It also prevents from graft–versus-host-disease (GVHD). A second approach to preventing graftrejection involves supplementing the marrow graftwith peripheral blood leukocytes. Some of the key drugs used immunosuppression arealemtuzumab, antithymocyte globulin, tacrolimus, methylprednisolone, methotrexate, sirolimus and mycophenolatemofetil etc. Second approach involves supplementing the marrow graft with peripheral blood leukocytes. There are many therapies are used in bone marrow transplant, most important is gene therapy. It is a type of hematopoietic stem cell transplantation in which the deficiency in a patient’s hematopoietic stem cell is rectified by gene correction. Currently gene therapy research is expanding. BMT market is expected to grow $56.9 billion in 2019, a compound annual growth rate of 22.3%. The UK, France and Germany are holding good market shares in the field of regenerative medicine and tissue engineering. There may be 25 million registered bone marrow donors worldwide, but only half of all patients are able to match with a donor Of the 712,000 units that exist worldwide, just 4% have enough blood cells to be used. The future offers the opportunity of and probability of new and exciting developments in BMT market developments. To know more, click on the link below:- https://www.kenresearch.com/healthcare/pharmaceuticals/bone-marrow-transplant/154215-91.html Related Reports:- https://www.kenresearch.com/healthcare/pharmaceuticals/bone-marrow-transplant-rejection-pipeline/52586-91.html https://www.kenresearch.com/healthcare/pharmaceuticals/bone-marrow-transplant-rejection/90787-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Sales@kenresearch.com +91-9015378249
    448 Posted by richa sharma
  • A bone marrow transplant is a procedure that infuses healthy blood stem cells into your body to replace your damaged or diseased bone marrow. A bone marrow transplant is also called a stem cell transplant. A bone marrow transplant may be necessary if bone marrow stops working and doesn't produce enough healthy blood cells. Bone marrow transplant (BMT) rejection is a complication that can occur after a stem cell or bone marrow transplant. This is occurring when newly transplanted donor cells attack the transplant recipient's body. It also happens when the cells from donor are not accepted by patient’s body and patient’s original condition comes back, called as relapse. The chance of BMT rejection is around 30%-40%, when the donor and recipients are related and it is 60%-80% when the donor and recipient are not related. According to study, “Bone Marrow Transplant Rejection - Pipeline Review, H2 2018” some of the major players operating in BMT rejection are Bellicum Pharmaceuticals, Inc., Bio-Cancer Treatment International Limited, Actelion Ltd, BiogenInc, -Myers Squibb Company, Cantex Pharmaceuticals, Inc., Boryung Pharmaceutical Co., Ltd., Bristol Capricor Therapeutics, Inc., Dr. Falk Pharma GmbH, Cell Source Inc., Escape Therapeutics, Inc., Fate Therapeutics, Inc., Gilead Sciences, Inc.,F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Kamada Ltd., KiadisPharma N.V., Kymab Limited, Kyorin Pharmaceutical Co., Ltd., MacroGenics, Inc., Mallinckrodt Plc, Medsenic, Mesoblast Limited,  Rigel Pharmaceuticals, Inc., Seattle Genetics, Inc., Sarepta Therapeutics, Inc., Sigmoid Pharma Limited, Taiga Biotechnologies Inc., Spherium Biomed S.L. There are many symptoms of BMT rejection such as chills, chest pain, fever, and drop in blood pressure, flushing, hives, nausea, and headache, funny taste in mouth and pain & shortness of breath. The some of the problem associated with bone marrow transplant rejection include abnormal lymph tissues growth, hormone changes, cataracts, relase, secondary cancer and organ damage and others. Moreover these problems are dependent on important factors such as patient’s health, patient’s age, the length & degree of immune system suppression and chronic gast versus host disease is present or not. Primarily two approach to prevent BMT rejection at the transplant centers. The first treatment includes immunosuppressive drugs. It prevents BMT rejection by eradicating host T-cells to allow acceptance of donor cells. It also prevents from graft–versus-host-disease (GVHD). A second approach to preventing graftrejection involves supplementing the marrow graftwith peripheral blood leukocytes. Some of the key drugs used immunosuppression arealemtuzumab, antithymocyte globulin, tacrolimus, methylprednisolone, methotrexate, sirolimus and mycophenolatemofetil etc. Second approach involves supplementing the marrow graft with peripheral blood leukocytes. There are many therapies are used in bone marrow transplant, most important is gene therapy. It is a type of hematopoietic stem cell transplantation in which the deficiency in a patient’s hematopoietic stem cell is rectified by gene correction. Currently gene therapy research is expanding. BMT market is expected to grow $56.9 billion in 2019, a compound annual growth rate of 22.3%. The UK, France and Germany are holding good market shares in the field of regenerative medicine and tissue engineering. There may be 25 million registered bone marrow donors worldwide, but only half of all patients are able to match with a donor Of the 712,000 units that exist worldwide, just 4% have enough blood cells to be used. The future offers the opportunity of and probability of new and exciting developments in BMT market developments. To know more, click on the link below:- https://www.kenresearch.com/healthcare/pharmaceuticals/bone-marrow-transplant/154215-91.html Related Reports:- https://www.kenresearch.com/healthcare/pharmaceuticals/bone-marrow-transplant-rejection-pipeline/52586-91.html https://www.kenresearch.com/healthcare/pharmaceuticals/bone-marrow-transplant-rejection/90787-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Sales@kenresearch.com +91-9015378249
    Oct 09, 2018 448
  • 09 Oct 2018
    “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2018", a clinical trial report by GlobalData throws light on the global trial scenario of the recurrent malignant glioma. It contains the trial numbers, trial enrolment, trial status and covers clinical trials by region, countries (G7 and E7), regions and phase. A trend analysis of the past years’ trials enrolment as well as analysis of the status of these trials, listings of on-going drug trials and a subsequent projection can help players to identify opportunities, markets and investments. Gliomas are tumours formed from the glial cells in human brain that are responsible for the support of the nerve cells. These are rapidly progressive and highly invasive brain tumours, classified into four grades depending on the severity of the occurrence. While there has been boom of development and evolution in research for the treatment of cancer; there has been comparatively little advancement in treating malignant glioma and reducing the recurrence of the disease. Novel therapeutics are being worked upon and organizations are participating in the global clinical trials to find effective treatments that could increase the survival chances as well as survival span of the patients. Some of the market players involved in these global trials of recurrent malignant glioma is known names of the global pharma industry. These includes F. Hoffmann-La Roche Ltd, Merck & Co Inc., Insys Therapeutics Inc., Eisai Co Ltd, AstraZeneca Plc, Novartis AG, Eli Lilly and Co, Takeda Pharmaceutical Co Ltd, Tactical Therapeutics Inc., Pfizer Inc. Current treatments for malignant glioma are multimodal. These are divided into chemotherapy, targeted drug therapy and radiation therapy, which are further divided into sub-categories. When it comes to the global market for glioma therapeutics, it has been dominated by North America and Europe, driven by their advanced technologies. However, Asia is believed to be the next competitor in near future, with countries like China, India, Japan and South Korea, already progressing in their research work and participation. Companies are eyeing these markets for strategic expansions and investments. The process is further being aided by support from government agencies in terms of policies and increase in research funding from private entities. The global clinical trials market is on rise and is expected to show significant growth in next decade. The factors driving this growth are expected to be, increasing globalization of clinical trials, advancement in technology and demand for more research in the biotech-medical field. However a couple of challenges that the market face are high attrition in the clinical trials-specially in case of cancer treatments and high prices of new- generation drugs. But, with the increase in population, diversity in the medical cases, as well as overall development of the emerging economies; the industry has shifted its focus to these markets. Thanks to the developments in globalization, new services and avenues have surfaced that now helps the mid-size and small size organizations and research institutes to have access to data and research platforms that were earlier only available with the biotech-pharma giants. To know more, click on the link below:- https://www.kenresearch.com/healthcare/pharmaceuticals/recurrent-malignant-glioma/154913-91.html Related Reports:- https://www.kenresearch.com/healthcare/pharmaceuticals/recurrent-malignant-glioma-pipeline/10207-91.html https://www.kenresearch.com/healthcare/pharmaceuticals/recurrent-malignant-glioma/10444-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Sales@kenresearch.com +91-9015378249
    505 Posted by richa sharma
  • “Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2018", a clinical trial report by GlobalData throws light on the global trial scenario of the recurrent malignant glioma. It contains the trial numbers, trial enrolment, trial status and covers clinical trials by region, countries (G7 and E7), regions and phase. A trend analysis of the past years’ trials enrolment as well as analysis of the status of these trials, listings of on-going drug trials and a subsequent projection can help players to identify opportunities, markets and investments. Gliomas are tumours formed from the glial cells in human brain that are responsible for the support of the nerve cells. These are rapidly progressive and highly invasive brain tumours, classified into four grades depending on the severity of the occurrence. While there has been boom of development and evolution in research for the treatment of cancer; there has been comparatively little advancement in treating malignant glioma and reducing the recurrence of the disease. Novel therapeutics are being worked upon and organizations are participating in the global clinical trials to find effective treatments that could increase the survival chances as well as survival span of the patients. Some of the market players involved in these global trials of recurrent malignant glioma is known names of the global pharma industry. These includes F. Hoffmann-La Roche Ltd, Merck & Co Inc., Insys Therapeutics Inc., Eisai Co Ltd, AstraZeneca Plc, Novartis AG, Eli Lilly and Co, Takeda Pharmaceutical Co Ltd, Tactical Therapeutics Inc., Pfizer Inc. Current treatments for malignant glioma are multimodal. These are divided into chemotherapy, targeted drug therapy and radiation therapy, which are further divided into sub-categories. When it comes to the global market for glioma therapeutics, it has been dominated by North America and Europe, driven by their advanced technologies. However, Asia is believed to be the next competitor in near future, with countries like China, India, Japan and South Korea, already progressing in their research work and participation. Companies are eyeing these markets for strategic expansions and investments. The process is further being aided by support from government agencies in terms of policies and increase in research funding from private entities. The global clinical trials market is on rise and is expected to show significant growth in next decade. The factors driving this growth are expected to be, increasing globalization of clinical trials, advancement in technology and demand for more research in the biotech-medical field. However a couple of challenges that the market face are high attrition in the clinical trials-specially in case of cancer treatments and high prices of new- generation drugs. But, with the increase in population, diversity in the medical cases, as well as overall development of the emerging economies; the industry has shifted its focus to these markets. Thanks to the developments in globalization, new services and avenues have surfaced that now helps the mid-size and small size organizations and research institutes to have access to data and research platforms that were earlier only available with the biotech-pharma giants. To know more, click on the link below:- https://www.kenresearch.com/healthcare/pharmaceuticals/recurrent-malignant-glioma/154913-91.html Related Reports:- https://www.kenresearch.com/healthcare/pharmaceuticals/recurrent-malignant-glioma-pipeline/10207-91.html https://www.kenresearch.com/healthcare/pharmaceuticals/recurrent-malignant-glioma/10444-91.html Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Sales@kenresearch.com +91-9015378249
    Oct 09, 2018 505